You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProMerck & Co. (MRK)
10 stories published on MRK since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Merck & Co. (MRK) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
CMS Drug Price Rule May Target Subcutaneous Keytruda and Opdivo, Hitting Merck and Bristol Myers
Direct news · High influence · Long term
CMS Proposes Extending Medicare Drug Price Negotiations to 2029, Pressuring Big Pharma Revenue
Drug pricing / FDA / IRA · High influence · Long term
Merck Stock: Physicians Say They Are Ready to Prescribe Its Oral PCSK9 Pill
Direct news · Medium influence · Short term
Merck Stock Jumps on FDA Approval of New Cholesterol Pill
Direct news · Medium influence · Long term
Merck's Lipfendra Cholesterol Pill Gets FDA Approval: Stock Implications
Direct news · Medium influence · Long term
Direct news
The most recent stories naming MRK directly, across all of our coverage.
Merck Stock: What the New HIV Pill Licensing Deal Means for MRK
Merck Stock: Physicians Say They Are Ready to Prescribe Its Oral PCSK9 Pill
Merck Stock Jumps on FDA Approval of New Cholesterol Pill
Merck's Lipfendra Cholesterol Pill Gets FDA Approval: Stock Implications
Pfizer Stock: FDA Approves PADCEV Plus Keytruda for Early Bladder Cancer
Merck's Keytruda Wins FDA Approval in Muscle-Invasive Bladder Cancer
FDA Approves Merck's Belzutifan Plus Keytruda Combination as Adjuvant Treatment, Expanding the Renal Cancer Market
CMS Drug Price Rule May Target Subcutaneous Keytruda and Opdivo, Hitting Merck and Bristol Myers
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved MRK, with the stories behind each.
Also monitored for MRK (no news in our coverage yet): FDA approvals & trial outcomes.
See the full picture
Sign up free to track MRK, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track MRK for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.